Protocol Raw — VC Investor Strategy¶

Version 1.4 | 12 April 2026 Replaces: v1.3 (March 2026) Aligned with: Business Plan v3.1, Growth Strategy v3.0, Growth Playbook v2.5, Financial Model v2.1, REF-MICRO-01 v2.0, Brand Voice v1.4

Key Changes in v1.4: Integrates the microbiological risk model (REF-MICRO-01 v2.0) into the investor narrative. New "Honest Bridge Narrative" section: we identified a structural production cost before launch, rebuilt the model, and the fix is the manufacturing bet that was always in the plan. Margin claims made phase-specific throughout (no single LTV:CAC number). Series A trigger aligned to M22 / £13.8M ARR with £15M raise. Bootstrap contingency numbers (784 customers / £889k ARR / £5k founder draw at M36) added as credibility point. Phase A empirical data (43 batches, 43 poultry tests) reframed as the primary evidence base for investors.

Investor Thesis¶

Raw dog food has stalled at 5-6% of the UK premium market. Not because demand is saturated, but because raw still behaves like a hobby. It requires research, recipe rotation, freezer management, portion calculation, and a leap of faith on safety. Premium buyers who would otherwise switch are stopped by a dual barrier: friction ("this seems like a lot of effort") and unverified safety ("is this actually safe?").

Bella & Duke partially solved this through emotional warmth and community. Butternut Box solved it by cooking the food. Neither provides verifiable safety evidence, and Butternut's cooking-based brand positioning makes a credible move into raw strategically difficult.

Protocol Raw removes both barriers at once. One complete recipe. Calorie-matched to each dog. Delivered on schedule. Every batch independently tested for Salmonella, Listeria, and Enterobacteriaceae before release. Results published via QR code.

The result: raw feeding that behaves like a trusted staple, not a tribal hobby. That is a category expansion story.

The verification layer is what makes defaultability defensible. Simplicity can be copied. Published batch testing data, accumulated over 18-24 months, is difficult to replicate quickly, especially for multi-SKU brands with existing supply chain commitments. The proof infrastructure is the moat.

The Honest Bridge Narrative¶

This is the v1.4 addition to the investor story, driven by REF-MICRO-01 v2.0.

The short version: We identified a structural production cost before launch, rebuilt the model honestly, and the fix is the manufacturing bet that was always in the plan.

The longer version:

The raw pet food category has a safety problem that most operators don't know about because they don't test. The FSA's 2026 survey of 380 frozen raw pet food samples found 20.8% Salmonella prevalence and 28.7% overall statutory failure across 50 brands. Protocol Raw tests every batch. That means we discover and destroy contaminated product rather than shipping it unknowingly. We found this before launch, not after. The REF-MICRO-01 v2.0 analysis documents the reject rate projections for our specific formulation: 4% during self-manufacture with our upstream poultry gate (Phase A, M0-M8), 18.6% at the co-packer without the gate (Phase B, M9-M27), 4% again when we rebuild the gate at scale in our own facility (Phase C, M34+).

The co-packer phase is an ugly but funded bridge. Seed pays for it. Contribution margin is 17-29% on the bridge, reflecting the honest cost of batch testing at 18.6% reject without ingredient control. Operating profitability is reached at M15 despite the waste. The business does not stop working; the margin just has to absorb the reject cost.

The structural fix is in-house manufacturing with upstream ingredient screening. Series A funds the facility build at M22. Build runs M23-M27 (£1.6M capex over 5 months), parallel production M28-M33 (in-house share ramps 15% to 90%), full in-house M34+. The poultry gate is reinstated at scale. COGS/kg drops from £3.30 to £2.90. Reject rate drops from 18.6% to 4%. Contribution margin reaches 48.6%. Operating margin reaches ~37%.

Why this story is stronger than the prior "category expansion + verification" pitch:

It is verifiable. Financial Model v2.1 contains the full yield arithmetic, three reject scenarios, and the M23-M27 capex schedule. Business Plan v3.1 contains the capital plan. REF-MICRO-01 v2.0 is the source analysis.
It kills its own downside. The prior bootstrap contingency (self-funded co-packer transition to £5k/month by M22) does not survive 18.6% reject economics. We killed it. The new bootstrap floor is self-manufacture only, viable indefinitely (784 customers, £889k ARR, £5k founder draw at M36 [CHECK against Bootstrap Growth sheet]).
It strengthens the moat. 28.7% of the category fails statutory criteria. Competitors cannot retrofit honest testing without hitting the same reject economics we carry through the bridge. We designed for these costs from day one.
It is already what top-tier premium operators did. Bella & Duke and Butternut Box both built in-house facilities at the revenue stage Protocol Raw reaches at Series A (~£13.8M ARR at M22). This is the category-standard path, not a novel bet.

LTV:CAC trajectory (not a single number):

Phase	Contribution LTV	Blended CAC	LTV:CAC	Payback
Phase B Early (M9-M12)	£251	£66	3.8:1	3.8 months
Phase B Late (M13-M22)	£416	£66	6.3:1	2.3 months
Phase C In-House (M34+)	£714	£66	10.8:1	1.4 months

The 3.8:1 during the funded bridge is above the 3:1 threshold most investors require. The 10.8:1 at full in-house is exceptional. Cite the trajectory, not a single number. Most DTC food businesses watch LTV:CAC erode with scale. Protocol Raw's improves structurally because the manufacturing transition simultaneously cuts COGS/kg and eliminates 18.6% production waste. See Financial Model v2.1 Part 7.

The strongest version of this story is: "This founder found a structural cost that most operators in the category have never even measured, killed his own backup plan because it no longer held, rebuilt the model honestly, and is now raising to fund the bridge to the manufacturing economics that permanently solve the problem."

Round Structure¶

This raise: Seed, £1.15M, close at M9 (VC Path alignment; outreach starts late Phase A as empirical micro risk data completes) Lead anchor: £400-600k from one institutional investor Remainder: Angels and strategic co-investors Process: Focused 6-8 week outreach starting M7 Future raise reference (Series A): £15M at M22 / £13.8M ARR trigger, funds facility build (£1.6M capex M23-M27) and UK expansion. Series A is not being raised now; it is referenced so seed investors can see the path to the next round and exit trajectory

Target Metrics for Fundraise¶

Metric	Target	Why It Matters
Customers (at Seed close, M9)	~542 per VC Path (~250-346 Phase A target prior to M9)	Self-manufacture capacity ceiling early, then scaling; statistical significance
Box-2 Retention	70%+	Product-market fit (industry: 40-60%, great: 70%+)
% New to Raw	50%+	Proves thesis: expanding market, not stealing share
CAC (Phase A)	£100-105 blended	Acquisition efficiency (95% paid at £110, 5% formal referrals)
CAC (Phase B Seed-funded, post-close)	£66-85 blended	Acquisition efficiency (scaling referral share toward 25%)
Contribution LTV (trajectory)	£251 → £416 → £714 by phase	Phase B Early → Phase B Late → Phase C In-House (Financial Model v2.1 Part 5)
Contribution LTV:CAC (trajectory)	3.8:1 → 6.3:1 → 10.8:1	Phase-specific, not a single number. 3.8:1 during the funded bridge is above the 3:1 fundable threshold; 10.8:1 at full in-house is exceptional
Published Batch Reports	40+ at M8 (~43 finished batches + 43 upstream poultry tests)	Phase A empirical evidence base. Zero failures across 43 batches gives 95% confidence that the true reject rate is below 6.7%. This validates the 4% Phase A / Phase C Conservative-case planning assumption
Self-Manufacture COGS	£3.50-4.50/kg improving through Phase A	Validated production economics
Phase A finished-batch reject rate	4% Conservative (REF-MICRO-01 v2.0 ACTIVE)	With poultry gate active; empirically validated by M8

Differentiator: By M8 (Seed outreach start), we have self-manufactured ~43 batches with the upstream poultry gate active, ~43 upstream Salmonella test results on incoming poultry deliveries, 100% finished-batch lab clearance target, published batch reports via QR codes, and a qualified co-packer ready for Phase B scale production. No other raw brand can show this. The ~43 batch empirical sample is large enough to validate planning assumptions statistically: zero failures across 43 batches gives 95% confidence that the true reject rate is below 6.7%, supporting the 4% Conservative case used throughout the Financial Model and Business Plan.

Pitch Framing by Fund Type¶

Same company, same capabilities, different emphasis depending on who you are talking to.

Cross-cutting: the honest bridge narrative. Regardless of fund type, lead any serious conversation with the honest bridge story (see section above). Investors respect founders who find structural costs before launch rather than after. The story is: "We rebuilt the financial model around a reject cost most operators in this category have never measured. The co-packer bridge is ugly but funded. The fix is the manufacturing bet that was always in the plan, triggered at Series A. Here is the Phase A empirical data that validates the end state." Use the fund-type-specific framings below for everything that sits around this core.

Consumer Insight Funds (JamJar, Active, Felix, Redrice, DLF, V3, Era)¶

Lead with: The latent cohort. Premium buyers stuck on Butternut or kibble because raw still feels like a project. Protocol Raw turns raw into a default. Verification is the proof layer that makes the simplicity credible.

Avoid leading with: Technical stack, automation percentages, infrastructure complexity.

Operational Leverage Funds (Kindred, MMC, Octopus, Connect, dmg ventures)¶

Lead with: Capital efficiency outcome. An evidence-led consumer brand built by a technical founder, achieving operational leverage that traditional CPG cannot match. AI-native from day one.

Avoid leading with: "Software company that happens to sell dog food" or heavy tooling detail without connecting it to business outcomes.

Category Redesign Funds (Seedcamp, LocalGlobe, Speedinvest, Creator)¶

Lead with: The dual-barrier structural problem AND the honest bridge. Raw feeding has stalled because no brand has solved both friction and safety. Protocol Raw redesigns the category by removing both barriers. Accumulated proof data and the 28.7% FSA statutory failure finding create a time-locked moat: competitors cannot retrofit honest testing without hitting the same reject economics we already price into the Seed raise. We identified the structural cost before launch, rebuilt the model, and the facility build at Series A is the fix.

Avoid leading with: Generic startup language or category buzzwords without the structural argument.

Media-for-Equity (Channel 4 Ventures, ITV AdVentures, dmg ventures)¶

Lead with: Consumer brand with strong DTC unit economics that can convert TV/media exposure directly into subscription revenue via the calculator funnel. Premium positioning means high LTV per impression.

Avoid leading with: Technical infrastructure (they care about consumer reach and brand story).

Tier 1 — Realistic Lead Candidates¶

These funds can lead the round, write £500k-£1.5M cheques, and move at startup speed.

1. JamJar Investments — PRIORITY #1¶

Overview: Founded by Innocent Drinks founders. Check size £500k-£3M, sweet spot £1.5M. Can lead rounds.

Why #1: Marleybones (£900k seed, Sept 2024) means they are actively deploying in premium pet food right now. Zero category education required.

Key Contact: Sophie Luck — Investor, food/beverage/pet specialist

Portfolio: Tails.com (exited to Nestle Purina 2018), Marleybones (led seed Sept 2024), Wild, Runna

Pitch Angle:

"You backed Marleybones for the premium fresh segment. Protocol Raw reaches the adjacent cohort that cooked and fresh brands are structurally unlikely to convert: the buyer who wants raw but has not started because it feels like a project and the safety is unverified. We made it simple, we made it verified, and we have 70% Box-2 retention to show it works."

Framing: Consumer insight. JamJar cares about category expansion and consumer behaviour shifts, not infrastructure detail.

2. Active Partners¶

Overview: Consumer-focused since 2004. Early-stage fund £250k-£1M, growth fund £3M-£15M. Philosophy: "Product is the ultimate differentiator."

Why Top Tier: KatKin (fresh cat food, 2023). Co-invested with JamJar on Marleybones. Invested in Healf, Creature Comforts, Freja.

Key Contact: Billy Fox (billy.fox@active.partners) for early-stage fund

Pitch Angle:

"You backed KatKin for the underserved premium cat segment. Protocol Raw does the same for raw dog food. The product IS the differentiator: one recipe, calorie-matched, every batch verified. Premium buyers who thought raw was too complicated discover it is easier than what they are already doing."

Framing: Product differentiation and consumer insight. Lead with how the product changes behaviour.

3. Mercia Ventures — NEW¶

Overview: UK-focused, £1-10M at seed to Series B. Backs exceptional founders building category-defining brands.

Why Top Tier: Has backed Pure Pet Food. Direct pet food category experience. Will understand subscription economics, cold chain logistics, and the competitive landscape immediately.

Key Contact: Jonathan Kruger (jonathan.kruger@mercia.co.uk)

Portfolio: Pure Pet Food, Heidi, Tutorful, Oddbox

Pitch Angle:

"You backed Pure Pet Food and understand pet subscription economics. Protocol Raw targets the premium segment that dehydrated is structurally unlikely to convert: buyers who want real raw food but need it to be simple and verified. One recipe, calorie-matched, every batch independently tested. We are not competing with Pure Pet Food. We are expanding the addressable market."

Framing: Consumer insight with category expansion. No portfolio conflict (dehydrated vs raw are different segments).

4. DLF Venture — NEW¶

Overview: Luxembourg-based, London office. £300k-£4m at seed to Series A. Focus on food & beverage, health & care.

Why Top Tier: Backed Edgard & Cooper (premium pet food, exited 2024). They have seen a premium pet food exit and know what the returns look like. Typically leads or co-leads.

Key Contact: Louis Kerschen (LinkedIn)

Portfolio: Edgard & Cooper (exited 2024), Nucao, Gimber, New Soul

Pitch Angle:

"You backed Edgard & Cooper and exited in 2024. Protocol Raw is the next generation of premium pet food: not just better ingredients, but verifiable safety. We remove the two barriers that cap raw at 5-6%: complexity and unverified safety. One recipe, calorie-matched, every batch tested."

Framing: Consumer insight with exit precedent.

5. LocalGlobe¶

Overview: Founded by Robin Klein and Saul Klein (Skype/LoveFilm pedigree). £500k-£2M at seed. 302 portfolio companies, 17 unicorns. "Cradle-to-IPO" with sister fund Latitude for Series B+.

Why Top Tier: One of UK's most active seed investors. Sector-agnostic but favour exceptional founders tackling significant, scalable opportunities. Fast decisions, partner-only team.

Key Contacts: Saul Klein, Robin Klein, Suzanne Ashman Blair

Portfolio: Wise, Citymapper, Zoopla, Graze (DTC food subscription, exited)

Pitch Angle:

"You backed Graze and understand DTC food subscription economics. Protocol Raw applies the same model to pet food, but with a structural moat: accumulated batch verification data that compounds over time and is difficult for multi-SKU competitors to replicate. We are not just building a brand. We are building the standard for how raw pet food should work."

Framing: Category redesign. Lead with structural moat and category-defining potential.

6. Seedcamp¶

Overview: Founded 2007. Check size: EUR500k-EUR1M. 477 portfolio companies, 9 unicorns, 2 IPOs (Wise, UiPath). EUR166M Fund VI (2023).

Why Top Tier: One of Europe's most established seed VCs. Massive angel syndicate and follow-on network. Invests in "category-defining wedges."

Key Contacts: Reshma Sohoni (Founding Partner), Carlos Espinal (Managing Partner), Sia Houchangnia (Partner)

Pitch Angle:

"Raw dog food is stuck as a hobby. Protocol Raw turns it into a default. One recipe solves the complexity. Batch verification solves the safety doubt. The proof data accumulates into a time-locked moat. This is a category redesign, not a better raw food brand."

Framing: Category redesign. Seedcamp invests in structural wedges, not product features.

7. Octopus Ventures¶

Overview: £1.7bn AUM. Average seed £4.7M. 345 portfolio companies, 17 unicorns. Consumer-specialist pod focused on marketplaces, gaming, consumer AI, vertical software.

Why Top Tier: Tails.com exit to Nestle 2018. ManyPets ($2B valuation). AllPlants (DTC food subscription). Deep experience with pet subscription scale and defensibility.

Key Contact: Matt Chandler (consumer pod, LinkedIn)

Portfolio: Tails.com (exited to Nestle), ManyPets, AllPlants, Zoopla, Depop, Elvie

Pitch Angle:

"You made money on Tails.com, which proved personalisation in pet food could scale. Protocol Raw is the next structural evolution: not just personalised portions, but verified safety and radical simplicity. One recipe, calorie-matched, every batch independently tested. We are reaching the premium segment that personalisation alone could not convert because it never resolved the trust question."

Framing: Operational leverage. Position as building on what Tails proved, not criticising it. Octopus appreciates scale infrastructure and defensibility.

8. Kindred Capital¶

Overview: Check size: average £700k, reserves 70% for follow-on. Fund III: £130M (2024). "Equitable venture" model where every founder becomes co-owner of the fund.

Why Top Tier: All partners are ex-operators. Love "company as system" stories. Partner-only team means fast decisions.

Key Contacts: Leila Rastegar Zegna (Founding GP, ex-Innocent Drinks), Chrys Chrysanthou (GP), Maria Palma (Partner)

Portfolio: Paddle ($1.4B valuation), LabGenius, Farewill

Pitch Angle:

"Protocol Raw is a company-as-system story. The founder self-manufactured ~43 batches with an upstream poultry gate before qualifying a co-packer. Those 43 batches produced the empirical micro risk dataset that validates the 4% reject rate assumption the entire financial model is built on. On top of that: operational leverage via GPT-4o Vision for lab result parsing, automated customer service triage, and infrastructure built for 100k customers from day one. This is a category where founders typically lack technical backgrounds. Protocol Raw is different."

Framing: Operational leverage. Lead with the system, the Phase A empirical evidence, and the automation rates.

9. Speedinvest (Marketplaces & Consumer)¶

Overview: Vienna-headquartered, London office. EUR700k-EUR1.3M typical seed. EUR350M Fund IV (2024).

Why Top Tier: Dedicated Marketplaces & Consumer team. Sameer Singh in London specifically covers network effects.

Key Contacts: Sameer Singh (Partner, London), Katharine Spooner

Pitch Angle:

"Protocol Raw accumulates proof data with every batch produced. That dataset compounds over time and is difficult to replicate quickly by a new entrant. The verification layer functions like compounding trust infrastructure: each data point makes the system more credible."

Framing: Category redesign. Frame batch testing accumulation as compounding trust capital. Sameer Singh looks for compounding dynamics and defensibility over time.

10. Connect Ventures¶

Overview: Founded 2012, London. $150k-$3M. "The Product VC." Low volume, high conviction (25 companies per fund).

Why Top Tier: "Product-first" thesis. "Becomes a standard" stories. Rory Stirling led Gousto at BGF, so understands cold chain DTC complexity.

Key Contacts: Pietro Bezza, Sitar Teli, Rory Stirling (ex-BGF, ex-MMC, led Gousto)

Pitch Angle:

"Protocol Raw is a product-first company where the product IS the verification system. The batch testing, QR codes, and proof portal are not marketing layers on top of food. They are the product. The food is the medium. The proof is the value. And the honest bridge narrative proves it: we found a structural cost (18.6% reject at co-packer, 28.7% statutory failure across the category per the FSA), rebuilt the model around it, and the manufacturing transition funded at Series A is the permanent fix."

Framing: Category redesign meets operational leverage. Rory Stirling will appreciate the cold chain complexity and the honest bridge story.

11. V3 Ventures — NEW¶

Overview: Consumer brands and platforms in beauty, personal care, food, and consumer lifestyle. £1M-£5M at seed and Series A. UK, EU, US.

Why Top Tier: Backed KatKin (premium cat food subscription). Same dynamic as Redrice with Untamed: cat vs dog means no portfolio conflict. Already understand subscription pet food unit economics.

Key Contact: hello@v3.ventures

Portfolio: SURI, Wild, Yepoda, HOLY, KatKin

Pitch Angle:

"You backed KatKin and understand premium pet subscription economics. Protocol Raw targets the raw dog food segment that no brand has made simple and verified enough for mainstream premium buyers. KatKin proved the model for cats. Protocol Raw does it for dogs, with batch verification as the defensibility layer."

Framing: Consumer insight with portfolio adjacency.

12. dmg ventures — NEW¶

Overview: £250k-£1.5M at pre-seed to Series A. Backed by UK's largest news media group (MailOnline, Metro). Offers "venture with a voice" through media partnership. Also makes £1M-£5M media-led investments at Series B+.

Why Top Tier: Explicitly wants "defensibility beyond the brand" at pre-seed and seed. Batch verification is exactly that. Media partnership with MailOnline and Metro is potentially enormous for awareness at seed stage. UK-focused with US/EU expansion.

Key Contact: Taos Edmondson (taos.edmondson@dmgventures.co.uk, LinkedIn)

Portfolio: Zoopla, F1 Arcade, SURI, Papier, Plum

Pitch Angle:

"Protocol Raw has defensibility beyond the brand: accumulated batch verification data that creates a time-locked competitive moat. The product turns raw feeding from a hobby into a default. We would benefit enormously from media partnership to reach premium dog owners at scale."

Framing: Operational leverage meets media-for-equity. Lead with defensibility (their stated criterion) then the media angle.

Tier 2 — Strong Co-Leads / Heavy Cheques¶

These funds can write significant cheques (£250k-£1M) alongside a Tier 1 lead.

13. Redrice Ventures¶

Overview: London seed-stage consumer brands. £500k-£3M. Led by experienced ex-founders and operators.

Why Strong Co-Invest: Untamed (led Series A 2023, followed Series B 2025) means premium pet food conviction. Cat vs dog = no conflict. Co-invests with Active Partners, Five Seasons.

Key Contact: Submit via Redrice website (all decks reviewed and replied to)

Pitch Angle:

"You led Untamed. Protocol Raw is the same premium positioning for raw dog food. The segment we target is buyers who would feed raw if it were as simple and verifiable as what they already buy. We made it simple. We made it verified."

14. Eka Ventures¶

Overview: £68M impact VC. £500k-£3M, prefer to lead. Thesis: sustainable consumption, consumer health.

Why Strong Co-Invest: Team track record includes Gousto (£1bn+) and Bloom & Wild (£500m+). Gousto's fresh food subscription with complex cold chain is the closest analogue to Protocol Raw. Co-invests with JamJar.

Key Contacts: Camilla Dolan (GP), Hamish Law (LinkedIn)

Impact Framing: Protocol Raw's formulation is built around organ meats, bone, and secondary cuts: ingredients that are byproducts of existing human food production, not competitors with it. Less processing than kibble. Precise calculations reduce food waste. Optimised cold chain logistics.

Pitch Angle:

"You backed Gousto: fresh food subscription with complex cold chain. Protocol Raw is the same operational DNA applied to pet food, with a verification layer that creates genuine defensibility. The formulation uses secondary cuts and organs, not premium human-grade meat, making it more environmentally defensible than lightly cooked competitors whose brands are built on premium cuts."

15. SFC Capital¶

Overview: UK's most active early-stage investor (822+ investments). £100k-£500k. SEIS/EIS focus. British Business Bank backing.

Why Strong Co-Invest: Fast-moving, good at syndicating angels. "Round saver" if Tier 1 stalls. SEIS/EIS expertise makes the round tax-efficient for angels.

Key Contact: Stephen Page (Founder & CEO)

Pitch Angle:

"Protocol Raw is a SEIS-eligible UK business targeting a £500M+ addressable market. 250-300 customers at 70% retention, with operational leverage that most consumer brands do not achieve until Series A."

16. Creator Ventures — NEW¶

Overview: £300k-£1.5M at pre-seed and seed. Consumer internet. Primarily US but active in UK and EU. Lead or follow.

Why Strong Co-Invest: Backed Wild (DTC subscription deodorant). Very similar model to Protocol Raw: subscription, premium, DTC, single-product focus. Will understand the mechanics immediately.

Key Contact: Sasha Kaletsky (sasha@creator.ventures)

Pitch Angle:

"You backed Wild and understand single-product DTC subscription economics. Protocol Raw applies the same model to raw dog food, with a verification layer that adds defensibility most DTC brands lack. Subscription, premium, one product, simple."

17. Era VC — NEW¶

Overview: Australian fund. £1.5M at pre-seed to Series A. Consumer brands across beauty, food & beverage, wellness. UK, EU, US, Australia.

Why Strong Co-Invest: Category-defining consumer brands in food & beverage is their explicit thesis. Claire Cherry leads European activity (ex-dmg ventures).

Key Contact: Claire Cherry (claire@era.vc)

Pitch Angle:

"Protocol Raw is a category-defining consumer brand in pet food. We are not iterating on existing raw. We are redesigning the category by removing the two barriers that have kept raw at 5-6%: complexity and unverified safety."

Tier 3 — Strategic / Follow-On Power¶

These funds add strategic value but are better approached after Tier 1/2 momentum.

18. Five Seasons Ventures¶

Overview: Pan-European food-tech VC, backed by Nestle, EIF, Bpifrance. EUR2-4M first cheques.

Why Tier 3: Series A energy. Butternut Box portfolio company creates a potential conflict. Slower diligence due to strategic LPs.

Key Contacts: Ivan Farneti, Niccolo Manzoni, Valerie Evans (valerie@fiveseasons.vc)

Pitch Angle (Manage Conflict):

"You backed Butternut for the convenience buyer. Protocol Raw reaches the cohort Butternut's cooking-based brand positioning makes structurally difficult to target: buyers who want raw to be as simple as cooked AND verifiably safe. We expand the addressable market."

19. Companion Fund (Mars Petcare / Digitalis Ventures)¶

Overview: $300M CVC managed by Digitalis. $3.45M avg seed.

Why Strategic (NOT Lead): Mars vet network (70k+ associates, 2.5k clinics) is valuable. Potential exit path. But slow, bureaucratic, potentially rights-heavy, may scare other VCs.

Key Contacts: Geoffrey W. Smith (Digitalis), Ben Jacobs (Companion Fund)

Pitch Angle:

"Protocol Raw creates a verification standard that could become the norm for how raw pet food is evaluated. The batch testing infrastructure is category infrastructure, not just brand infrastructure."

20. Felix Capital¶

Overview: £1.2bn AUM. $1M-$20M. Creative class / digital lifestyle.

Conflict Warning: Pure Pet Food (£15M Oct 2024) in portfolio.

Why Approach (With Leverage): Category creation stories. Only approach after JamJar/Active going well.

Pitch Angle:

"Pure Pet Food captures the convenience seeker. Protocol Raw captures the premium buyer who wants raw to be as easy as cooked AND verifiably safe. Different customer, different psychology, expandable market."

Framing: Consumer insight. Felix cares about "does this become a thing people talk about."

21. MMC Ventures¶

Overview: ~$1bn AUM. £1M-£10M. "Data-driven" investor. 4 unicorns including Synthesia.

Why Tier 3: Not a classic consumer fund, but Protocol Raw's operational leverage makes it interesting.

Key Contacts: Simon Menashy (AI specialist), Mina Samaan (GP)

Portfolio: Gousto, Bloom & Wild, Signal AI, Synthesia

Pitch Angle:

"Protocol Raw is an evidence-led consumer brand built by a technical founder. GPT-4o Vision for lab result parsing, automated triage with sentiment detection, and infrastructure designed for 100k customers from day one. The microbiological risk analysis (REF-MICRO-01 v2.0) is a 50-page document with detection maths, three reject-rate scenarios, and the yield arithmetic for the co-packer bridge. The result is operational leverage that traditional CPG cannot match, built on a foundation of honest cost modelling."

Framing: Operational leverage. "Evidence-led consumer brand with unusually strong operational leverage" is the credible version. The REF-MICRO-01 analysis is a strong diligence artefact for data-driven investors.

22. Pembroke VCT¶

Overview: £255M VCT, part of Oakley Capital. £1M-£10M. Co-invests with JamJar, Active Partners.

Why Syndicate Participant: Pasta Evangelists exit (to Barilla, 2.3x). Prefer £1M+ revenues so better for Series A, but if JamJar or Active leads, Pembroke likely follows.

23. ITV AdVentures — NEW¶

Overview: Media-for-equity arm of ITV. £1M-£5M of media. Broad criteria: any fast-growing consumer brand that could benefit from TV advertising scale.

Why Strategic: Has backed PitPat (pet tech). TV advertising at seed stage is normally impossible. ITV reaches mass UK audiences.

Key Contact: Callum Taylor (callum.taylor@itv.com)

Pitch Angle:

"Protocol Raw is a premium subscription brand with strong unit economics. TV exposure drives calculator visits, and the calculator converts at high rates because it removes all friction: enter your dog's details, see your plan. The funnel is built for mass-reach acquisition."

24. Channel 4 Ventures — NEW¶

Overview: Media-for-equity arm of Channel 4. £2M-£10M of media. 50M viewers/month. Reputation for young/affluent viewers.

Why Strategic: Channel 4's audience skews toward exactly Protocol Raw's target demographic: younger, affluent, urban professionals who are the premium pet food buyer.

Key Contact: John Gagalang (jgagalang@channel4.co.uk)

Pitch Angle:

"Protocol Raw targets premium dog owners in London and the Home Counties. Channel 4's audience profile overlaps precisely with our buyer: affluent, engaged, willing to pay for quality. The subscription model means every viewer who converts becomes recurring revenue."

25. Stonebridge — NEW¶

Overview: Permanent capital, £250k-£20m, stage-agnostic. Backs founders who leverage technology to improve lives. Invested £25M+ in last 12 months.

Why Strategic: Permanent capital means patient money. The AI-native operations story plays well with their technology-forward thesis.

Key Contact: James Cox (jc@stonebridge.gg)

Portfolio: Revolut, Castore, Simba Sleep, Townhouse

Pitch Angle:

"Protocol Raw is a premium consumer brand with technology-driven operational leverage. The founder built the entire technical infrastructure before launch, achieving automation rates that most consumer brands do not reach until Series B. The result is capital efficiency that fundamentally changes the growth economics."

Tier 3 also-worth-tracking:¶

Slingshot (£500k-£2m, strong brands with healthy margins, Western Europe) — backed Wild, Yepoda. Contact: marly@slingshot.ventures

Pentland Ventures (£1M-£5M, "eat, live, move better") — backed Love Corn, Misfits. Contact: Simon Lum / Lucas Giacomelli on LinkedIn

Boxfund (£250k-£2M, impact-consumer brands, SEIS/EIS) — 4-5 investments per year, always takes board seat. Contact: tom@boxfund.co.uk

Joyance (US-based, £50k-£1.5M, health/consumer goods) — backed Jude, Luna Daily. Contact: Thibault Vanvincq on LinkedIn

Yeo Ventures (£250k-£500k, natural/healthy food systems) — Yeo Valley family. Contact: Chris Gale on LinkedIn

Batch Sequencing Strategy¶

Week 1 — Batch 1 (Core Lead Shots)¶

Fund	Contact	Why First
JamJar	Sophie Luck	Marleybones Sept 2024, exact category
Active Partners	Billy Fox	KatKin + Marleybones co-invest
Mercia	Jonathan Kruger	Pure Pet Food in portfolio
DLF	Louis Kerschen	Edgard & Cooper exit 2024

Week 2 — Batch 2 (Secondary Leads + Category Redesign)¶

Fund	Contact	Why Second
LocalGlobe	Saul Klein / Suzanne Ashman Blair	Systems thinking, Graze pedigree
Seedcamp	Reshma Sohoni / Carlos Espinal	Category-defining wedge
Octopus	Matt Chandler	Tails.com exit, pet conviction
Kindred	Leila Zegna	Company-as-system

Week 3 — Batch 3 (Co-Leads + New Additions)¶

Fund	Contact	Role
V3 Ventures	hello@v3.ventures	KatKin in portfolio
Redrice	Website submission	Untamed in portfolio
Creator	Sasha Kaletsky	Wild in portfolio
Eka	Camilla Dolan / Hamish Law	Impact + Gousto pedigree
dmg ventures	Taos Edmondson	Media partnership
Era	Claire Cherry	Category-defining F&B

Week 4+ — Batch 4 (Strategic + Media)¶

Fund	Contact	Role
Five Seasons	Valerie Evans	Strategic (manage Butternut conflict)
Companion Fund	Ben Jacobs	Mars network
ITV AdVentures	Callum Taylor	Media-for-equity
Channel 4	John Gagalang	Media-for-equity
Stonebridge	James Cox	Patient capital
SFC Capital	Stephen Page	Angel syndicate / round saver

Cold Outreach Template¶

Subject: Raw dog food, redesigned — 280 customers, 72% retention, 65% new to raw

Hi [First name],

Protocol Raw makes raw feeding defaultable: one complete recipe, 
calorie-matched plan, every batch independently tested before release.

Early London traction: 280 customers, 72% Box-2 retention, 65% new 
to raw.

We think we are unlocking a different customer than normal raw brands: 
premium upgraders who want a trusted default, not a feeding hobby.

I saw you backed [relevant portfolio company] — happy to share more.

Anton
[LinkedIn] | [One-pager]

Why this works: - Thesis-led: "makes raw feeding defaultable" says what the company does in five words - Three proof points in one line: customers, retention, market expansion - The insight line ("different customer than normal raw brands") is the thing that makes an investor stop scrolling - "Trusted default, not a feeding hobby" is the category creation argument in seven words - Easy ask, not metrics-heavy

Q&A Preparation¶

Why did customers churn? (Track churn reasons from Day 1)
Payback period? Phase-specific: 3.8 months (Phase B Early) → 2.3 months (Phase B Late) → 1.4 months (Phase C In-House) at blended CAC of £66. The 3.8 months at the worst point of the funded bridge is still below the 6-month threshold typical for DTC food subscriptions.
Month 3, 4, 5 retention? (Build cohort analysis)
How verified "new to raw"? (Signup question: "What do you currently feed?")
NPS? (Implement post-Box-2)
Why can't Butternut Box do this? (Their brand is built on "we cook for safety." Moving into raw would create significant brand tension and undermine their core positioning. This is a strategic constraint, not a capability gap.)
What is the moat? (1) Accumulated batch verification data, compounding over time, difficult for multi-SKU competitors to replicate. (2) FSA data shows 28.7% of the raw pet food category fails statutory criteria; competitors retrofitting honest testing hit the same 18.6% reject economics Protocol Raw absorbs through the co-packer bridge. (3) The in-house facility with upstream poultry gate reinstated at scale (funded at Series A) is the structural fix competitors cannot easily replicate without raising growth capital. (4) Phase A empirical data (43 batches, 43 poultry tests) gives us a statistical validation most operators never collect. Multi-year competitive window.
Why now? (Dual conversion barrier, not market saturation. Premium buyers are blocked by friction AND safety doubt. No brand has solved both. Butternut solved both by cooking. We solve both better: simpler format plus verified safety.)
Why did you self-manufacture? (Founder production knowledge, validated COGS before co-packer lock-in, published batch history for credibility. Now transitioning to co-packer for scale.)
Is your LTV:CAC of 4:1 good enough? The single-number LTV:CAC of 4:1 from v1.3 is superseded. The v1.4 honest answer is a phase trajectory: 3.8:1 → 6.3:1 → 10.8:1 (Phase B Early → Phase B Late → Phase C In-House) at blended CAC of £66. 3.8:1 during the funded bridge is above the 3:1 fundable threshold; 10.8:1 at full in-house is exceptional. The trajectory reflects the reject cost during the co-packer bridge (17-29% contribution margin) and the structural improvement when the manufacturing transition reinstates the poultry gate at scale. This is a stronger story than a single number because it shows how the economics improve with scale: most DTC food businesses watch this ratio erode; Protocol Raw's improves structurally.
What if the co-packer transition fails? We can continue self-manufacturing indefinitely (see the Bootstrap Floor credibility point in the Alternatives section: 784 customers, £889k ARR, £5k founder draw at M36 [CHECK against Bootstrap Growth sheet], poultry gate active, milkround delivery). The co-packer is a bridge to the Series A-funded facility, not a destination. Phase A proves we have production capability; the co-packer is for scale, not survival. If the co-packer transition fails at M9, we revert to self-manufacture and raise Seed from a slower-growing but profitable base.
Is raw feeding environmentally defensible? (Protocol Raw's formulation uses organ meats, bone, and secondary cuts: byproducts of existing human food production, not competitors with it. We do not claim "human-grade" because we do not need to. This is inherent to whole-prey formulation.)
Is the friction-first thesis validated? (Working hypothesis. Phase A is designed to test it through smoke tests, onboarding questions, and exit interviews. The dual-layer model and verification moat remain valid regardless of which barrier ranks first, because both layers are required for conversion and retention.)
Why is your co-pack phase contribution margin so low (17-29%)? Because we test every batch. At an 18.6% finished-batch reject rate (Central case, REF-MICRO-01 v2.0), we produce 22.85% more than we ship. The co-packer will not run our upstream poultry gate for a single client, so we cannot screen out the highest-prevalence Salmonella input before production. The cost is real, survivable, and funded by Seed. It is eliminated when we move in-house at M34. The 17-29% CM on the bridge is the honest cost of honest testing; 48.6% at Phase C in-house is where the business model actually lives.
Why is in-house manufacturing required, not optional? The only way to reinstate the upstream poultry gate at scale is to own the facility. The co-packer will not run per-delivery Salmonella screening for a single client. Without the gate, the reject rate stays at 18.6% permanently. That caps contribution margin at ~29%, which is insufficient to fund aggressive acquisition or support the premium-multiple narrative. In-house manufacturing cuts COGS/kg from £3.30 to £2.90 AND cuts reject rate from 18.6% to 4%. Both together deliver 48.6% contribution margin.
How do you know the 4% Phase A reject rate will hold at Phase C scale? Phase A (M0-M8) produces approximately 43 finished batches and 43 upstream poultry test results. Zero failures across 43 batches gives 95% confidence that the true reject rate is below 6.7%. The Control Panel in the Financial Model has three scenarios for Phase A (Low 2%, Conservative 4% ACTIVE, Stress 9%); if Phase A data comes in worse than 9%, we have a structural formulation problem that predates the co-packer transition and must be addressed first. The Seed thesis rests on this data, not on the planning estimate.
Why not HPP (High Pressure Processing)? The original REF-MICRO-01 analysis positioned HPP as a potential Phase B solution. Subsequent review established that HPP toll processing is not practically available in the UK for this application. The Control Panel still contains an HPP section but it is disabled (month 99). The structural solution is in-house manufacturing with the poultry gate reinstated.

If VCs Pass: Alternatives¶

Option 1: Angel-only round (£200-300k). Skip institutional VCs. 12-18 months runway. Return with £1M ARR.

Option 2: Bootstrap further (the Self-Manufacture Floor). Self-manufacture only, poultry gate active, milkround delivery. 784 customers, £889k ARR, £5k net founder draw at M36 [CHECK against Bootstrap Growth sheet]. Viable indefinitely without external funding. This is a documented floor, not a consolation prize: the business does not depend on external capital for survival, but the VC Path reaches £54M ARR by M36 vs the bootstrap floor's £889k, so bootstrap is genuinely the answer to "what if we don't raise?" not "what's plan B if we underperform?" The prior bootstrap path (self-funded co-packer transition to £5k/month by M22) is no longer viable because co-packing at 18.6% reject destroys margins before self-funding can close the transition. The new bootstrap path is self-manufacture only. See Business Plan v3.1 § No-Raise Contingency.

Why the bootstrap path is a credibility point with investors: Removes the VC-or-bust dynamic from the fundraising conversation. Reduces urgency leverage in term sheet negotiations. Phase A empirical data (43 batches, 43 poultry tests) accumulates regardless of whether Seed closes. At M24+ with 400+ profitable self-manufacture customers, published proof data, and a validated 4% reject rate, we can return to investors from a fundamentally stronger position.

Option 3: Revenue-based financing. Once £20-30k MRR: Clearco, Uncapped, Shopify Capital. Non-dilutive.

Option 4: Strategic money. Pet industry angels (exited pet businesses). Blender/packer or co-packer with commercial interest.

Funds Explicitly Excluded¶

The Craftory — Has stated in writing that raw feeding and human-food-chain pet food is "environmentally a backwards step." Category-level ideological objection that cannot be overcome in a pitch meeting.

Summary: The Complete Universe¶

Tier 1 — Realistic Lead Candidates (12 funds) 1. JamJar — Sophie Luck 2. Active Partners — Billy Fox 3. Mercia — Jonathan Kruger 4. DLF Venture — Louis Kerschen 5. LocalGlobe — Saul/Robin Klein, Suzanne Ashman Blair 6. Seedcamp — Reshma Sohoni, Carlos Espinal 7. Octopus — Matt Chandler 8. Kindred — Leila Zegna 9. Speedinvest — Sameer Singh 10. Connect Ventures — Rory Stirling 11. V3 Ventures — hello@v3.ventures 12. dmg ventures — Taos Edmondson

Tier 2 — Strong Co-Leads (4 funds) 13. Redrice — Website submission 14. Eka — Camilla Dolan / Hamish Law 15. SFC Capital — Stephen Page 16. Creator Ventures — Sasha Kaletsky 17. Era VC — Claire Cherry

Tier 3 — Strategic / Follow-On (8+ funds) 18. Five Seasons — Valerie Evans 19. Companion Fund — Ben Jacobs 20. Felix — TBD (with leverage) 21. MMC Ventures — Simon Menashy 22. Pembroke VCT — TBD 23. ITV AdVentures — Callum Taylor 24. Channel 4 Ventures — John Gagalang 25. Stonebridge — James Cox

Also tracking: Slingshot, Pentland, Boxfund, Joyance, Yeo Ventures

Bottom Line: Hit the metrics. Run a disciplined process. The venture story is not "verified raw dog food." It is "the company that made raw behave like a trusted staple rather than a tribal hobby." That is a category expansion story, and category expansion is what raises seed rounds.

Version History¶

Version	Date	Changes
1.4	12 April 2026	Microbiological risk model integration (REF-MICRO-01 v2.0 / BP v3.1 / FM v2.1 / GS v3.0 / GP v2.5 alignment). New "Honest Bridge Narrative" section rewriting the investor pitch around: "We identified a structural production cost before launch, rebuilt the model, and the fix is the manufacturing bet that was always in the plan." Margin claims made phase-specific (LTV:CAC trajectory 3.8:1 → 6.3:1 → 10.8:1 at blended CAC of £66). Target Metrics table rewritten with phase-specific Contribution LTV (£251 → £416 → £714) and Phase A empirical evidence base (43 batches, 43 poultry tests). Round Structure updated: Seed £1.15M at M9 (was £1.0-1.5M close before Month 6). Series A reference added (£15M at M22 / £13.8M ARR trigger). Q&A updated: 4 revised + 4 new (reject rate, in-house requirement, Phase A validation, HPP). Alternatives Option 2 rewritten with Bootstrap Growth numbers (784 / £889k / £5k at M36 [CHECK]). Fund pitch angles augmented for Kindred, Connect, and MMC.
1.0	January 2026	Initial release. 16 funds across 3 tiers.
1.1	February 2026	Metrics updated for self-manufacture model (250-300 customers, Contribution LTV:CAC). Pitch angles updated with self-manufacture credibility. Cold outreach template revised. Framing notes added per fund type. Aligned to BP v2.4.
1.2	March 2026	Thesis upgraded from "verified raw / safety anxiety" to "raw made defaultable." All pitch angles rewritten. Fund-type framing renamed (Consumer Insight, Operational Leverage, Category Redesign). "Software company that happens to sell dog food" removed. Certainty language softened. Aligned to BP v2.9.
1.3	March 2026	9 new funds added (Mercia, DLF, V3, dmg ventures, Creator, Era, ITV AdVentures, Channel 4, Stonebridge). Environmental defensibility Q&A added. Friction-first validation Q&A added. The Craftory explicitly excluded with rationale. Active Partners contact updated to Billy Fox. Media-for-equity framing category added. Batch sequencing expanded to 4 waves. Cold outreach template rewritten as thesis-led (insight line added). Octopus pitch angle reframed as "next structural evolution" (builds on Tails, does not critique it). Total universe: 25+ funds. Aligned to BP v2.9, Brand Voice v1.4.